$1.84
Insights on Fortress Biotech Inc
Revenue is down for the last 3 quarters, 34.75M → 13.03M (in $), with an average decrease of 38.6% per quarter
Netprofit is down for the last 3 quarters, -5.04M → -17.73M (in $), with an average decrease of 87.5% per quarter
In the last 1 year, Novo Nordisk A/s has given 71.8% return, outperforming this stock by 149.1%
In the last 3 years, Novo Nordisk A/s has given 235.1% return, outperforming this stock by 331.9%
1.09%
Downside
Day's Volatility :3.53%
Upside
2.46%
32.61%
Downside
52 Weeks Volatility :88.36%
Upside
82.72%
Period | Fortress Biotech Inc | Index (Russel 2000) |
---|---|---|
3 Months | -16.74% | 0.0% |
6 Months | -29.21% | 0.0% |
1 Year | -77.3% | 0.0% |
3 Years | -96.93% | -22.6% |
Market Capitalization | 37.4M |
Book Value | $1.19 |
Earnings Per Share (EPS) | -6.03 |
PEG Ratio | -0.1 |
Wall Street Target Price | 24.75 |
Profit Margin | -64.05% |
Operating Margin TTM | -280.63% |
Return On Assets TTM | -34.13% |
Return On Equity TTM | -1739.64% |
Revenue TTM | 85.1M |
Revenue Per Share TTM | 7.95 |
Quarterly Revenue Growth YOY | 4.8% |
Gross Profit TTM | -85.7M |
EBITDA | -111.6M |
Diluted Eps TTM | -6.03 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -4.71 |
EPS Estimate Next Year | -3.21 |
EPS Estimate Current Quarter | -1.73 |
EPS Estimate Next Quarter | -1.58 |
What analysts predicted
Upside of 1245.11%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 26.9M | ↓ 85.67% |
Net Income | -84.1M | ↑ 25.83% |
Net Profit Margin | -313.02% | ↓ 277.37% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 36.6M | ↑ 36.26% |
Net Income | -51.8M | ↓ 38.43% |
Net Profit Margin | -141.44% | ↑ 171.58% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 45.6M | ↑ 24.49% |
Net Income | -103.0M | ↑ 98.78% |
Net Profit Margin | -225.85% | ↓ 84.41% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 68.8M | ↑ 50.86% |
Net Income | -164.8M | ↑ 60.05% |
Net Profit Margin | -239.6% | ↓ 13.75% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 75.7M | ↑ 10.11% |
Net Income | -213.9M | ↑ 29.78% |
Net Profit Margin | -282.42% | ↓ 42.82% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 84.5M | ↑ 11.58% |
Net Income | -60.6M | ↓ 71.65% |
Net Profit Margin | -71.75% | ↑ 210.67% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 16.4M | ↓ 0.75% |
Net Income | -57.4M | ↑ 226.1% |
Net Profit Margin | -350.19% | ↓ 243.61% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 12.4M | ↓ 24.23% |
Net Income | -22.1M | ↓ 61.51% |
Net Profit Margin | -177.9% | ↑ 172.29% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 17.4M | ↑ 39.88% |
Net Income | -24.8M | ↑ 12.05% |
Net Profit Margin | -142.51% | ↑ 35.39% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 34.8M | ↑ 99.88% |
Net Income | -5.0M | ↓ 79.64% |
Net Profit Margin | -14.52% | ↑ 127.99% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 19.9M | ↓ 42.6% |
Net Income | -9.3M | ↑ 83.92% |
Net Profit Margin | -46.52% | ↓ 32.0% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 13.0M | ↓ 34.67% |
Net Income | -17.7M | ↑ 91.09% |
Net Profit Margin | -136.08% | ↓ 89.56% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 141.0M | ↓ 42.67% |
Total Liabilities | 121.3M | ↓ 3.35% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 226.4M | ↑ 60.59% |
Total Liabilities | 153.9M | ↑ 26.92% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 328.8M | ↑ 45.23% |
Total Liabilities | 131.8M | ↓ 14.33% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 396.5M | ↑ 20.58% |
Total Liabilities | 170.6M | ↑ 29.42% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 294.3M | ↓ 25.78% |
Total Liabilities | 244.3M | ↑ 43.16% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 167.5M | ↓ 43.08% |
Total Liabilities | 165.9M | ↓ 32.07% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 294.3M | ↓ 9.04% |
Total Liabilities | 244.3M | ↑ 9.93% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 263.6M | ↓ 10.45% |
Total Liabilities | 243.7M | ↓ 0.22% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 180.7M | ↓ 31.43% |
Total Liabilities | 196.7M | ↓ 19.32% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 150.5M | ↓ 16.69% |
Total Liabilities | 163.8M | ↓ 16.71% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 167.5M | ↑ 11.28% |
Total Liabilities | 165.9M | ↑ 1.31% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 164.6M | ↓ 1.72% |
Total Liabilities | 168.6M | ↑ 1.59% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -98.8M | ↑ 15.71% |
Investing Cash Flow | 18.8M | ↓ 146.8% |
Financing Cash Flow | 50.6M | ↓ 67.16% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -95.0M | ↓ 3.93% |
Investing Cash Flow | 20.1M | ↑ 6.76% |
Financing Cash Flow | 146.7M | ↑ 189.67% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -83.7M | ↓ 11.88% |
Investing Cash Flow | -7.2M | ↓ 135.65% |
Financing Cash Flow | 172.4M | ↑ 17.51% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -116.5M | ↑ 39.27% |
Investing Cash Flow | 40.5M | ↓ 665.52% |
Financing Cash Flow | 149.0M | ↓ 13.58% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -47.8M | ↑ 10.56% |
Investing Cash Flow | -5.0M | ↑ 459.91% |
Financing Cash Flow | 18.6M | ↑ 397.01% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -43.2M | ↓ 9.66% |
Investing Cash Flow | -5.0M | ↑ 0.0% |
Financing Cash Flow | 22.2M | ↑ 19.17% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -33.3M | ↓ 22.97% |
Investing Cash Flow | -2.0M | ↓ 59.22% |
Financing Cash Flow | -30.4M | ↓ 236.93% |
Sell
Neutral
Buy
Fortress Biotech Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Fortress Biotech Inc | 6.18% | -29.21% | -77.3% | -96.93% | -92.84% |
Moderna, Inc. | 21.03% | 85.08% | 14.68% | -28.27% | 659.22% |
Regeneron Pharmaceuticals, Inc. | 3.22% | 20.54% | 31.88% | 92.14% | 229.83% |
Novo Nordisk A/s | 8.85% | 36.12% | 71.83% | 234.04% | 457.53% |
Vertex Pharmaceuticals Incorporated | 16.81% | 32.76% | 40.6% | 124.79% | 171.36% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Fortress Biotech Inc | NA | NA | -0.1 | -4.71 | -17.4 | -0.34 | NA | 1.19 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.14 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 28.89 | 28.89 | 1.46 | 44.13 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 46.97 | 46.97 | 2.36 | 3.5 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 29.59 | 29.59 | 0.53 | 17.08 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Fortress Biotech Inc | Buy | $37.4M | -92.84% | NA | -64.05% |
Moderna, Inc. | Buy | $54.6B | 659.22% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $108.0B | 229.83% | 28.89 | 29.45% |
Novo Nordisk A/s | Buy | $602.6B | 457.53% | 46.97 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $117.5B | 171.36% | 29.59 | 39.46% |
CVI Holdings LLC
Nantahala Capital Management, LLC
Rosalind Advisors, Inc.
Armistice Capital, LLC
Altium Capital Management, LP
Vanguard Group Inc
fortress biotech, inc. is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. fortress plans to develop and commercialize products that it acquires both directly as well as indirectly by establishing subsidiary companies, also known as fortress companies. the company will leverage its biopharmaceutical business expertise and drug development capabilities to help the fortress companies achieve their goals. additionally, the company will provide funding and management services to each of the fortress companies and from time to time the company and the fortress companies will seek licensing, partnerships, joint ventures, and/or public and private financings to accelerate and provide additional funding to support their research and development programs.
Organization | Fortress Biotech Inc |
Employees | 186 |
CEO | Dr. Lindsay Allan Rosenwald |
Industry | Health Technology |
A Spac I Acquisition Corp
$1.84
-2.65%
Keyarch Acquisition Corp
$1.84
-2.65%
Connexa Sports Technologies Inc
$1.84
-2.65%
Us Value Etf
$1.84
-2.65%
First Wave Biopharma Inc
$1.84
-2.65%
Global X Msci Next Emerging
$1.84
-2.65%
Fat Projects Acquisition Corp
$1.84
-2.65%
Goal Acquisitions Corp
$1.84
-2.65%
Capital Link Global Fintech
$1.84
-2.65%